IN THE UNITE SES PATENT AND TRADEMARK OFFIC

In re Application of:

Stuart A. Fine et al

Application No:

JUL 2 3 20

Filed:

June 4, 2001

For:

Compositions and Methods for Treatment of Glucose Metabolism

Disorders

Examiner: Not yet known

Art Unit:

1614

Attorney Docket No. AKT-053.02

#### CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this Request for Correction of Filing Receipt is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to Assistant Commissioner for Patents, Office of Initial Patent Examination Customer Service Center, Washington, D.C. 20231, on July 20, 2001.

## REQUEST FOR CORRECTION OF FILING RECEIPT

**Assistant Commissioner for Patents** Office of Initial Patent Examination Customer Service Center Washington, DC 20231

Sir:

Please make the following corrections in the formal Filing Receipt, a copy of which is enclosed and highlighted for your convenience, for the above-identified patent application:

Please correct the state where Stuart A. Fine lives from "ID" to --IL--.

Please rearrange the data under "Domestic Data as Claimed by Applicant" to read:

-- This application is a 371 of PCT/US99/21377 09/17/1999, which claims benefit of 09/156,102 09/17/1998 and 60/126,489 03/26/1999--.

Should there be any questions concerning this request, the Examiner is invited to contact the undersigned at (617) 832-1169.


Respectfully Submitted,

Date: July 20, 2001

Customer No: 25181 Patent Group Foley, Hoag & Eliot LLP One Post Office Square Boston, MA 02109-2170

Kingsley L. Taft Reg. No. 43,946 Tel. (617) 832-1000 Fax. (617) 832-7000

20/464612.1



RECEIVE SEP 0 6 2001 TECH CENTER 1600 UNITED STATES PATENT AND TRADEMARK

IND CLAIMS TOT CLAIMS GRP ART UNIT FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS APPLICATION NUMBER FILING DATE 728 AKT-053.02 1614 09/787.325 06/04/2001

**CONFIRMATION NO. 9479** 

FOLEY, HOAG & ELIOT, LLP PATENT GROUP ONE POST OFFICE SQUARE

OC000000006222617

**FILING RECEIPT** 

Date Mailed: 06/25/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

25181

BOSTON, MA 02109

Stuart A. Fine, Northbrook, JD; 11 Kevin J. Kinsella, La Jolla, CA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/21377 09/17/1999 WHICH IS A CHEOF 09/156,102 09/17/1998 (2003) WHICH CLAIMS BENEFIT 60/126,489 03/26/1999

Foreign Applications

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

PATENT DEPT. DOCKETING

Title

Compositions and methods for treatment of glucose metabolism disorders

Page 2 of 4

Date: 06/25/2001

119 Preliminary Class

Team: OIPE

1001 1000 10100 10100 10100 10100 10100 10100 10100 10100 10100 10100 10100 10100 10100 10100 10100 10100 10100

Data entry by: NGUYEN, SON

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Cod of Federal Regulations, 5.11 & 5.15

### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

# PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231